Renastart
Dietary SupplementRenastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
NCT Number: NCT02825784
A multicenter, open label, uncontrolled study to evaluate the acceptability, tolerability, and nutritional suitability of a medical food (Renastart, Vitaflo International Ltd) specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD)
Looking for future studies?
Notify MeUp to 10 year
All sexes
Interventional
Not applicable
Universitatsklinikum Bonn, Bonn, Germany
A multicenter, open label, uncontrolled study to evaluate the acceptability, tolerability, and nutritional suitability of a medical food (Renastart, Vitaflo International Ltd) specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD)
Primary Objective To investigate the nutritional suitability of Renastart in children aged 10 years and under with CKD, particularly with respect to the dietary management of hyperkalemia and the maintenance / improvement of growth.
Secondary Objectives To investigate the acceptance, compliance, palatability, and tolerance of Renastart in children aged under 10 years with CKD.
A total of 15 children with CKD will be enrolled in the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
Time frame: Baseline, week 8, week 16
To evaluate the nutritional suitability of Renastart, specifically in relation to management of hyperkalemia via blood tests
Time frame: Baseline, week 8, week 16
To monitor the maintenance / improvement of growth over the course of the study.
Time frame: Baseline, week 8, week 16
To monitor the maintenance / improvement of growth over the course of the study.
Time frame: Throughout the 16 weeks
To evaluate the palatability of Renastart when taken orally via a patient questionnaire.
Time frame: Throughout the 16 weeks
To evaluate the GI tolerance of Renastart when taken orally or by enteral feeding tube via a patient questionnaire.
Time frame: Throughout the 16 weeks
To evaluate patient compliance with Renastart administration when taken orally or by enteral feeding tube via a patient questionnaire.
Vitaflo International, Ltd
Industry
A Multicenter, Open Label, Uncontrolled Study to Evaluate the Acceptability, Tolerability and Nutritional Suitability of Renastart: Specially Formulated to Meet the Unique Nutritional Needs From Birth to 10 Years With Chronic Kidney Disease
Acronym: Renastart
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07054905
Chronic Disease, Chronic Kidney Disease
Daejeon, South Korea
View Trial DetailsNCT01371747
Cardiovascular Diseases, Chronic Disease
Karlovac, Croatia
View Trial DetailsNCT01493024
Chronic Disease, Chronic Kidney Disease
Tempe, Arizona, United States
View Trial DetailsNCT05090865
Chronic Disease, Chronic Kidney Disease
Winnipeg, Manitoba, Canada
View Trial Details